Recurrence Rate During 5-Year Period After Suspension of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Aug 10

PMID 39124583

Authors

Shinichiro Chujo

Hisashi Matsubara

Yoko Mase

Kumiko Kato

Mineo Kondo

Affiliations

Soon will be listed here.

Abstract

To determine the recurrence rate of neovascular age-related macular degeneration (nAMD) during a 5-year period after the suspension of anti-vascular endothelial growth factor (anti-VEGF) treatments. Thirty-four eyes of 34 nAMD patients who met the inclusion criteria and were treated by anti-VEGF drugs were studied. All met the treatment suspension criteria and were followed for 5 years after the suspension of the anti-VEGF treatment. Patients with a recurrence within one year were placed in Group A, and patients with a recurrence between 1 and 5 years were placed in Group B. The rate and time of a recurrence were analyzed using the Kaplan-Meier method. We also examined whether there were differences in the baseline factors of age, sex, subtype, treatment period, and treatment interval between Groups A and B. Twenty-five of 34 eyes (73.5%) had a recurrence within 5 years of stopping the anti-VEGF treatments. Thirteen (52.0%) of the 25 eyes had a recurrence within 1 year, 4 (16.0%) eyes between 1 and 2 years, 4 (16.0%) eyes between 2 and 3 years, 2 (8%) between 3 and 4 years, and 2 eyes (8%) between 4 and 5 years. The baseline factors were not significantly different between Groups A and B. The results showed that the recurrence rate was highest within one year after the suspension of the anti-VEGF treatments, with a number of recurrences one year after the suspension. Clinicians should remember that nAMD may recur several years after the suspension of anti-VEGF treatments.

References

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y . Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009; 116(11):2135-40. DOI: 10.1016/j.ophtha.2009.04.017. View

Schmidt-Erfurth U, Kaiser P, Korobelnik J, Brown D, Chong V, Nguyen Q . Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2013; 121(1):193-201. DOI: 10.1016/j.ophtha.2013.08.011. View

Zhong Z, He Z, Yu X, Zhang Y . Intravitreal Injection Is Associated with Increased Posterior Capsule Rupture Risk during Cataract Surgery: A Meta-Analysis. Ophthalmic Res. 2021; 65(2):152-161. DOI: 10.1159/000521576. View

Wykoff C, Ou W, Brown D, Croft D, Wang R, Payne J . Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study. Ophthalmol Retina. 2019; 1(4):314-321. DOI: 10.1016/j.oret.2016.12.004. View

Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T . Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001; 85(10):1153-7. PMC: 1723746. DOI: 10.1136/bjo.85.10.1153. View

Ohji M, Takahashi K, Okada A, Kobayashi M, Matsuda Y, Terano Y . Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020; 37(3):1173-1187. PMC: 7089719. DOI: 10.1007/s12325-020-01236-x. View

Aslanis S, Amren U, Lindberg C, Epstein D . Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen. Ophthalmol Retina. 2021; 6(1):15-20. DOI: 10.1016/j.oret.2021.03.010. View

Kim S, Park S, Byun S, Park K, Suh H . Incremental economic burden associated with exudative age-related macular degeneration: a population-based study. BMC Health Serv Res. 2019; 19(1):828. PMC: 6852978. DOI: 10.1186/s12913-019-4666-0. View

10.

Wong W, Su X, Li X, Cheung C, Klein R, Cheng C . Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2):e106-16. DOI: 10.1016/S2214-109X(13)70145-1. View

11.

Munk M, Arendt P, Yu S, Ceklic L, Huf W, Ebneter A . The Impact of the Vitreomacular Interface in Neovascular Age-Related Macular Degeneration in a Treat-and-Extend Regimen with Exit Strategy. Ophthalmol Retina. 2019; 2(4):288-294. DOI: 10.1016/j.oret.2017.07.010. View

12.

Brown K, Yannuzzi N, Smiddy W, Gregori N, Berrocal A, Haddock L . Rhegmatogenous Retinal Detachment after Intravitreal Injection. Ophthalmol Retina. 2020; 5(2):178-183. DOI: 10.1016/j.oret.2020.07.007. View

13.

Chaikitmongkol V, Sagong M, Lai T, Tan G, Ngah N, Ohji M . Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society. Asia Pac J Ophthalmol (Phila). 2021; 10(6):507-518. PMC: 8673847. DOI: 10.1097/APO.0000000000000445. View

14.

Bjerager J, van Dijk E, Holm L, Singh A, Subhi Y . Previous intravitreal injection as a risk factor of posterior capsule rupture in cataract surgery: a systematic review and meta-analysis. Acta Ophthalmol. 2022; 100(6):614-623. DOI: 10.1111/aos.15089. View

15.

Matsubara H, Matsui Y, Miyata R, Ichio A, Chujo S, Enomoto H . Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting. Graefes Arch Clin Exp Ophthalmol. 2022; 260(6):1867-1876. PMC: 9061688. DOI: 10.1007/s00417-021-05526-0. View

16.

Cho H, Jeon Y, Yoon W, Yoon J, Kim J, Kim J . Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission. Sci Rep. 2022; 12(1):15662. PMC: 9485132. DOI: 10.1038/s41598-022-19400-4. View

17.

Porta M, Striglia E . Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2019; 15(2):199-210. DOI: 10.1007/s11739-019-02253-7. View

18.

Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y . Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica. 2011; 226(3):145-50. DOI: 10.1159/000329863. View

19.

Jin I, Tang D, Gengaroli J, Nicholson Perry K, Burlutsky G, Craig A . Cross-sectional study evaluating burden and depressive symptoms in family carers of persons with age-related macular degeneration in Australia. BMJ Open. 2021; 11(9):e048658. PMC: 8438959. DOI: 10.1136/bmjopen-2021-048658. View

20.

Nguyen V, Vaze A, Fraser-Bell S, Arnold J, Essex R, Barthelmes D . Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Ophthalmol Retina. 2019; 3(8):623-628. DOI: 10.1016/j.oret.2019.05.013. View